CA-based biotechnology company Tr1X secures $75M in series A round funding. The Column Group led the investment, and Alexandria Ventures and NEVA SGR also participated.
The business plans to use the money to support the quick and efficient development of its unique pipeline of allogeneic-engineered Treg and CAR-Treg cell therapies, which are being used to treat severe autoimmune illnesses that impact millions of people globally.
Read also – WA-based Oleria Secures $33.1M in Series A Round Funding
Tr1X is a biotechnology business that aims to develop treatments for inflammatory and immunological disorders. Allogeneic cell treatments are being developed for diseases with a high unmet medical need through its pipeline.
The business is now developing TRX103, its first experimental Tr1 cell treatment, which it intends to test in a Phase 1 study to shield patients receiving mismatched hematopoietic stem cell transplants from Graft versus Host Disease (GvHD).
Read also – Conn.-based Kusari Secures $8m in Pre-Seed & Seed Funding
The company is working on pipeline programmes to treat numerous B-cell related autoimmune disorders, diabetes, and inflammatory bowel disease.
Tao Fu, MBA, and Katherine A. High, M.D., were named Independent Directors; William Lis was named CEO and Director; Maria Grazia Roncarolo, M.D., Scientific Founder, was named President and Head of R&D and Director.
Read also – Boston-based Digital Onboarding Secures $58M in Funding
About Tr1X
A biotechnology business called Tr1X Inc. (sometimes known as “Trix”) is devoted to creating cutting-edge cellular immunotherapies for those suffering from inflammatory and autoimmune disorders.
Read also – Boston-based Ratio Therapeutics Secures $50M in Series B Round Funding
The company creates first-in-class cell therapy solutions using its patented platform with the goal of reestablishing immune system balance and homeostasis, which promotes long-term tolerance.
